Expertise in
2
conditions

Richard Letourneau

Montreal, QC, CA 
Expertise in
2
conditions
Montreal, QC, CA 

Overview

Richard Letourneau practices practicing medicine in Montreal, Canada.

Mr. Letourneau is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Liver Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Hepatectomy.

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Montreal, QC H2X0C1, Canada
Other Locations
Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

12 Total Publications

Oncological outcomes associated with primary-first, liver-first and synchronous resection strategies in synchronous colorectal liver metastases.
Oncological outcomes associated with primary-first, liver-first and synchronous resection strategies in synchronous colorectal liver metastases.
Journal: Surgical oncology
Published: April 27, 2026

Frequently Asked Questions about Richard Letourneau

Is Richard Letourneau a top-rated expert for Hepato-Pancreato-Biliary Surgery?

MediFind is an objective health platform that identifies experts based on real-world data. Richard Letourneau is classified as an Distinguished expert for Hepato-Pancreato-Biliary Surgery, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Richard Letourneau participate in research or clinical trials?

Yes. Richard Letourneau has published 12 articles and abstracts on conditions like Hepato-Pancreato-Biliary Surgery. You can view a list of Richard Letourneau's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Letourneau's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile